What was Bristol-Myers Squibb’s revenue performance last quarter?
Bristol-Myers Squibb beat analysts’ revenue expectations by 3.9%, reporting revenues of $11.2 billion.
Yanuki
ARTICLE DETAIL
Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026 | Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect | Is Tesla Stock Going to $1,000? | Why the Nasdaq Is Holding Up Better Amid Geopolitical Tensions | Walmart vs BJ's Wholesale: Which Retailer Is a Better Buy? | Institutional Investors Increase Holdings in Invesco QQQ | ExxonMobil (XOM) Stock Analysis: Retail Investors and Market Trends in 2026 | Warren Buffett's Oil Bet: Analyzing Occidental Petroleum (OXY) and the Energy Market in 2026 | Tesla's Risks and Investment Alternatives | Micron Stock: Supply Tightness and Growth Potential in 2026
Finance / Earnings
Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect
Bristol-Myers Squibb (BMY) is set to report its Q2 earnings this Thursday. Investors are keen to see if the company can maintain its strong performance from last quarter, where it beat revenue expectations by 3.9%. This article provides a p...
Key Insights
- Analysts expect Bristol-Myers Squibb’s revenue to decline 6.7% year-on-year to $11.38 billion.
- Adjusted earnings are expected to come in at $1.13 per share.
- Analyst sentiment has turned bearish with 5 downward revisions to revenue estimates in the last 30 days.
- Bristol-Myers Squibb has a history of exceeding revenue expectations, beating estimates by an average of 3% over the last two years.
- The average analyst price target for Bristol-Myers Squibb is $56.05, compared to the current share price of $46.98.
In-Depth Analysis
Bristol-Myers Squibb's upcoming earnings report is crucial for investors to gauge the company's current financial health and future prospects. The expected revenue decline of 6.7% is a significant reversal from the 8.7% increase in the same quarter last year. This shift is primarily due to evolving market dynamics and increased competition within the biopharmaceutical sector.
Analysts' estimates have been trending downward, indicating concerns about the company's ability to maintain its growth trajectory. However, Bristol-Myers Squibb has consistently outperformed expectations in the past, suggesting a potential for a positive surprise. Monitoring key drugs and pipeline developments will be essential during the earnings call.
Compared to its peers, Merck recently reported disappointing earnings, missing revenue estimates by 1.1%. The overall pharmaceuticals segment has seen share prices decline by 1.8% over the last month. Bristol-Myers Squibb, however, has bucked this trend, with its stock price rising by 1.5% during the same period. This relative strength may indicate investor confidence in the company's long-term strategy.
FAQ
What are analysts expecting for this quarter’s revenue?
Analysts expect Bristol-Myers Squibb’s revenue to decline 6.7% year-on-year to $11.38 billion.
Has analyst sentiment been positive or negative leading up to the earnings release?
Analyst sentiment has grown increasingly bearish, with revenue estimates seeing 5 downward revisions over the last 30 days.
Takeaways
- Monitor Bristol-Myers Squibb’s revenue and earnings performance against analyst expectations.
- Pay attention to any updates on key drugs and pipeline developments during the earnings call.
- Consider the company’s history of exceeding expectations when evaluating its potential.
- Be aware of the bearish analyst sentiment and potential challenges facing the company.
Discussion
Do you think Bristol-Myers Squibb will beat earnings expectations? Let us know!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.